{"text": "Studies have shown that obesity can affect the pharmacokinetics of\n\nantipsychotics, leading to changes in drug concentrations (Kaplan et al.,\n\n2017). For instance, a study on olanzapine found that obese patients had\n\nhigher plasma concentrations compared to non-obese patients. This may be\n\nattributed to the increased volume of distribution in obese individuals.\n\nEfficacy of Antipsychotics in Obese Patients\n\nResearch has also investigated the efficacy of antipsychotics in obese patients.", "embedding": []}